PHATHOM PHARMACEUTICALS INC (PHAT) Stock Income Statement
USA - NASDAQ:PHAT - US71722W1071 - Common Stock
13.04 USD
-0.24 (-1.81%)
13.04 USD
0 (0%)
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 147.19M | 55.25M | 682.00K | 0.00 | 0.00 | |||
| Cost Of Goods | 18.77M | 7.97M | 167.00K | N/A | N/A | |||
| Gross Profit | 128.42M | 47.28M | 515.00K | N/A | N/A | |||
| Operating Expenses | 341.90M | 324.75M | 167.83M | 172.44M | 135.08M | |||
| Research and Development | 33.87M | 34.08M | 49.90M | 71.44M | 72.34M | |||
| Selling, General, and Administrative Expenses | 308.03M | 290.66M | 117.93M | 101.00M | 62.74M | |||
| Operating Income | -213.47M | -277.47M | -167.31M | -172.44M | -135.08M | |||
| Interest Income/Expense | -60.94M | -56.85M | -34.09M | -25.17M | -6.75M | |||
| Other Income/Expense | -135.00K | -8.00K | -188.00K | -110.00K | -60.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | -2.00M | |||
| Income Before Taxes | -274.55M | -334.33M | -201.59M | -197.72M | -143.88M | |||
| Net Income | -274.55M | -334.33M | -201.59M | -197.72M | -143.88M | |||
| EBITDA | -212.78M | -276.67M | -166.74M | -171.82M | -134.56M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.81 | -5.29 | -3.93 | -5.05 | -4.72 | |||
| Non GAAP EPS | -3.82 | -5.35 | -3.88 | -5.05 | -3.89 | |||
| Statistics | ||||||||
| Gross Profit Margin | 87.25% | 85.57% | 75.51% | N/A | N/A | |||
| Profit Margin | -186.53% | -605.09% | -29558.94% | N/A | N/A | |||
| Operating Profit Margin | -145.03% | -502.18% | -24532.55% | N/A | N/A | |||
All data in USD